Progress in cancer care takes more than innovation. It takes collaboration to turn scientific advances into meaningful impact for people living with cancer. At Novartis, we are partnering with organizations such as Europa Uomo to support men living with prostate cancer through ongoing collaboration, dialogue and shared learning. Because progress is stronger when we build it together. #ReimaginingOncology #ASCO26 #WeGoTogether #NovartisOncology
About us
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
- Website
-
http://www.novartis.com
External link for Novartis
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Basel, Baselstadt
- Type
- Public Company
- Specialties
- Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology, Chemistry, xRNA, Radioligand, and Gene and cell therapy
Locations
Employees at Novartis
Updates
-
A journey with Multiple Sclerosis (MS) doesn't start with a diagnosis. It starts with the first symptom - and remaining aware of them continues to help guide the way forward. It's inspiring to see so many stories shared for the MS International Federation (MSIF)'s #MyMSDiagnosis campaign. On this #WorldMSDay, each story highlights a unique journey of a person living with MS – sharing a very personal understanding of their body, its signals and symptoms. The obvious, the subtle, and those in between – noticing and talking about the full spectrum of symptoms ensures that these experiences shape their care. People living with MS know their MS better than anyone, which makes their voices the most powerful tool during their journeys. That’s why we support building informed, caring communities and systems that support people diagnosed with MS – today and every day! #MultipleSclerosis #MSAwareness #KnowYourMS #ChangesinYourMS
Today is World MS Day! 🌍 World MS Day brings the global MS community together to raise awareness, share stories and campaign for change. As we mark the final year of the #MyMSDiagnosis campaign, we are advocating for early and accurate diagnosis for everyone living with MS. 📢 MSIF is proud to co-ordinate World MS Day together with our members. Hear from MSIF Chair Mario Alberto Battaglia in this special World MS Day video message. Let's stand in solidarity with people affected by MS worldwide. 🙌 Together, we are stronger than MS. 🧡 Learn more about World MS Day: https://worldmsday.org/ Find out more about the MS International Federation: https://www.msif.org/ #WorldMSDay #MyMSDiagnosis
-
Cancer is constantly evolving and so must the way we approach it. At Novartis, we are reimagining oncology together through bold science and a commitment to people living with cancer. We push beyond today’s limits because stopping at first isn’t enough. We strive to make a meaningful difference where it matters most. #ReimaginingOncology #ASCO26 #BoldScience #NovartisOncology
-
Progress in oncology depends on who comes next to push the science forward. At Novartis, we are supporting the next generation of oncology researchers, through initiatives such as the Novartis Oncology Young Canadian Investigator Awards in Canada. Congratulations to the 2026 award winners.
(Français ci-dessous) Supporting the next generation of oncology researchers is essential to advancing the future of care in Canada. Novartis Canada is proud to announce the 2026 recipients of the Novartis Oncology Young Canadian Investigator Awards (NOYCIA). For over 20 years, this program has helped advance early-career researchers whose work is shaping the future of health. Congratulations to Amal Aljuhani, MD, MSc, Nihar Desai, MD, DM, Anna-Maria Lazaratos, Chloe Lim, Luxiga Thanabalachandran, Syed Irteza Abbas Shamsi, Samuel chan, Fernando Pikabea Diaz, François Jobin Gervais, Malek Hannouf, on this achievement. To learn more about this year’s winners, read the full announcement here: https://lnkd.in/e3wVq4QH #ReimaginingMedicineTogether #WeAreNovartis #NOYCIA #ASCO2026 -- Soutenir la prochaine génération de chercheurs en oncologie est essentiel pour faire progresser l’avenir des soins au Canada. Novartis Canada est fier d’annoncer les lauréats et lauréates 2026 des Prix du jeune chercheur canadien en oncologie de Novartis (NOYCIA). Depuis plus de 20 ans, ce programme contribue à faire progresser des chercheurs en début de carrière dont les travaux façonnent l’avenir de la santé. Félicitations à Amal Aljuhani, MD, MSc, Nihar Desai, MD, DM, Anna-Maria Lazaratos, Chloe Lim, Luxiga Thanabalachandran, Syed Irteza Abbas Shamsi, Samuel chan, Fernando Pikabea Diaz, François Jobin Gervais, Malek Hannouf, pour cette réalisation. Pour en savoir plus sur les lauréats de cette année, consultez le communiqué complet ici : https://lnkd.in/eSw-NK8m #RéinventerLaMédecineEnsemble #NousSommesNovartis #NOYCIA #ASCO2026
-
Giselle wants to create a world where more people can live full, healthy lives. Working at Novartis, she has the chance to make that dream a reality. Here she can thrive, together with a community of colleagues who share her purpose. Find opportunities to match your purpose at https://lnkd.in/ez5FBRba #ThriveTogether #NovartisCareers
-
At Novartis, expanding access to medicines starts with meeting people where they are. Korab Zuka shares how our community health programs work with local partners to redesign care and reduce health gaps.
Early detection shouldn’t depend on where you were born, or where you live now. But too often, it does. The persistent health gaps we still see aren’t about lack of willingness. They reflect systems that haven’t always been designed with every community in mind. Barriers to healthcare aren’t an artificial construct. For many communities, they are real, everyday issues ranging from distance to the nearest clinic to mistrust in the health system and limited or negative past experiences. So, instead of imposing solutions not always fit for purpose, what if we started by asking communities themselves what gets in their way, and then act on it? That’s why at Novartis, we look closely at where needs are greatest and work with communities to understand the barriers they face. From there, we redesign programs alongside them and partner with organizations already rooted locally. Together, we help people access education, screenings, diagnosis, and ongoing care. Our new Inclusive Health Accelerators are built on this approach. Drawing on what we’ve learned from existing programs, we’re now scaling partnerships across several U.S. cities to support early detection and treatment of breast and prostate cancer. Find out where we’re launching and how we’re delivering measurable, scalable community health solutions in TIME Magazine: https://lnkd.in/eMFB7x2Q If you’re working on prevention, what’s one design change that would make your system work better for the communities you work with?
-
-
Arti is fulfilling a lifelong ambition with Novartis. Ever since she contracted malaria as a little girl, she has been driven to understand the mechanisms of human disease. Today, she is helping to deliver a new generation of breakthroughs as part of our neuroscience team – reimagining medicine for patients everywhere. Find out how you can pursue your purpose at https://lnkd.in/gpUjVhUT #ThriveTogether #NovartisCareers
-
When everyone can take part, we all go further. As a proud partner of the Special Olympics World Winter Games Switzerland 2029, we’re making a four-year commitment to inclusion, supporting participation, dignity, and belonging in sport, in the workplace, and across society. Because inclusion isn’t symbolic, it’s something we build together. https://lnkd.in/gJZVM5-j #Inclusion #PoweringPotential
Inclusion is something we build together.
-
Novartis delivered strong growth in priority brands and recent launches during Q1 2026, while US generic erosion weighed on results as expected. We continued to advance our pipeline with innovation milestones, a completed acquisition and announced early-stage deals. With the momentum we are seeing across the business, we remain on track to deliver our full year guidance. Link to press release: https://lnkd.in/gCaPwCtQ #NVSQ126
-
At only 12 weeks old, Wonder was admitted to a hospital in Ghana with life-threatening malaria. Until recently, there were no medicines designed for babies his weight. Wonder was one of the first babies treated with a new antimalarial for newborns and young infants under 5kg. Soon, more babies like Wonder may be able to receive appropriate care, as the World Health Organization today has prequalified this product, taking another essential step toward enabling greater access across regions endemic with malaria in Africa. Find out more in Novartis Live Magazine: https://lnkd.in/ggQMf9qm #WorldMalariaDay Medicines for Malaria Venture | Tedros Adhanom Ghebreyesus | Daniel Ngamije Madandi